The Business Research Company, a research publisher and consulting firm, published its Biologics Global Market Report 2018. The report covers biologics, healthcare services, pharmaceutical drugs, and medical equipment markets.
The FDA is aiming to cut the time-to-market and the development costs for new drugs. This will help drive growth in the biologics market, where over 1,000 drugs are currently under development, to 9.6% year-on-year from its recent rate of 5.4%.
The changes being implemented or considered by the FDA include allowing organ-on-chip trials to be substituted for animal trials in the early stages of the process, allowing the inclusion of non-trial data from patients, and changing the end-point benchmark from proving that the drug extends overall survival to showing that it prolongs the time a patient lives without the disease getting worse. These changes will increase the rate of approvals in the US biologics market.
Some key findings from the report include:
Read the full report here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.